{"DataElement":{"publicId":"7587930","version":"1","preferredName":"Therapeutic Procedure Agent Chemotherapy Clinical Trial Protocol Dose Modification Vincristine Dose Modification Delay Reason Vincristine","preferredDefinition":"Question to identify whether a patient had a dose modification of chemotherapy drug vincristine due to a reason specified in the research protocol.","longName":"VCR_DOSE_MOD_PROTRSN_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7587922","version":"1","preferredName":"Therapeutic Procedure Agent Chemotherapy Clinical Trial Protocol Dose Modification Vincristine","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]_Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","longName":"2512834v1.0:7587920v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7587920","version":"1","preferredName":"Agent Chemotherapy Clinical Trial Protocol Vincristine Dose Modification","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.:A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]:A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04):Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","longName":"7587920v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Trial Protocol","conceptCode":"C142451","definition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC4534AF-7BD9-07CC-E053-4EBD850AEEDE","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC4534AF-7BEA-07CC-E053-4EBD850AEEDE","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7588091","version":"1","preferredName":"Dose Modification Delay Reason Vincristine","preferredDefinition":"Text terms to describe the reason a dose of a substance or agent was modified, delayed, or changed in schedule._The active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.","longName":"7588091v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682950","version":"1","preferredName":"No","longName":"5682950","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0F5D-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC459519-A3CE-747E-E053-4EBD850A4B49","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"Yes, due to other toxicity","valueDescription":"Toxicity","ValueMeaning":{"publicId":"4615972","version":"1","preferredName":"Toxicity","longName":"4615972","preferredDefinition":"The finding of bodily harm due to the poisonous effects of something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09172D7F-C118-E939-E050-BB89AD434D48","latestVersionIndicator":"Yes","beginDate":"2014-11-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-30","modifiedBy":"ONEDATA","dateModified":"2014-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC459519-A3E2-747E-E053-4EBD850A4B49","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"Yes, due to hepatic toxicity","valueDescription":"Hepatic Toxicity","ValueMeaning":{"publicId":"3404793","version":"1","preferredName":"Hepatic Toxicity","longName":"3404793","preferredDefinition":"Refers to the liver.: Toxicity; the degree to which something is poisonous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatic","conceptCode":"C13308","definition":"Pertaining to, affecting, or associated with the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA9519D4-D5E3-734E-E040-BB89AD43494A","latestVersionIndicator":"Yes","beginDate":"2012-03-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2012-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC459519-A3F6-747E-E053-4EBD850A4B49","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7588090","version":"1","preferredName":"Dose Change Vincristine Reason","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:The act of alteration or modification; changed or altered in form or character.:A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04):An explanation of the cause of some phenomenon or action.","longName":"C25488:C25446:C933:C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC459519-A3A8-747E-E053-4EBD850A4B49","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC459519-A3B9-747E-E053-4EBD850A4B49","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Did the patient require a dos","type":"Preferred Question Text","description":"Did the patient require a dose modification of vincristine due to protocol defined dose modifications?","url":null,"context":"COG"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Did patient require dose modification/omission of vincristine dose due to protocol-specified dose modifications?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC4549D4-6749-4EF5-E053-4EBD850AB508","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"CLOHNES","dateModified":"2022-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}